Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Teva Branded Pharmaceutical Products R&D, Inc.
Age
30–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have completed the Week 26 visit of TVP 1012/133 (Visit 06) in accordance with the protocol.
Women must be postmenopausal, surgically sterile, or using adequate birth control methods. Women of childbearing potential must have a negative pregnancy test at Baseline/Month 0.
Patients must be willing and able to give informed consent.
You may not be if
Serious or severe, test drug-related (probable or definite) adverse reaction in study TVP 1012/133.
Premature discontinuation from study TVP 1012/133 for any reason.
A clinically significant or unstable medical or surgical condition which would preclude safe and complete study participation. Such conditions may include cardiovascular, pulmonary hepatic, renal, metabolic diseases or malignancies as determined by medical history, physical exam, skin evaluation, laboratory tests, chest x-ray, or ECG.
Clareo Health | Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.
